UnitedHealth, Amedisys Reach Tentative Merger Deal With DOJ

UnitedHealth Group and Amedisys Inc. have reached a tentative settlement with the US Justice Department, resolving a lawsuit that challenged their $3.3 billion merger. The agreement mandates the divestiture of at least 164 home health and hospice facilities and requires Amedisys to pay a $1.1 million civil penalty for falsely certifying responses to antitrust regulators. This resolution effectively clears a significant regulatory hurdle, paving the way for the completion of the acquisition.

Analysis

UnitedHealth Group (UNH) and Amedisys (AMED) have reached a tentative settlement with the US Department of Justice, clearing a significant regulatory hurdle for their proposed $3.3 billion merger. The agreement resolves the DOJ's antitrust lawsuit by mandating the divestiture of at least 164 home health and hospice facilities, a material concession designed to preserve competition. Additionally, Amedisys will pay a $1.1 million civil penalty for non-compliance with information requests, a sum that is financially negligible compared to the transaction's value. This resolution signals a clear path forward for the acquisition, allowing UNH to advance its strategic expansion into the home health sector, albeit with a reduced asset base post-divestiture. The more positive sentiment for AMED (0.6) versus UNH (0.3) reflects the increased certainty of the deal's closure for Amedisys shareholders, while for UnitedHealth, the benefit is tempered by the cost of the required divestments.

Key Decisions for Investors

• For Amedisys shareholders, the settlement significantly de-risks the merger's completion, narrowing the arbitrage spread and making a hold strategy until deal closure more compelling.
• Investors in UnitedHealth should reassess the long-term accretion and synergy potential of the deal, as the forced divestiture of 164 facilities reduces the acquisition's immediate scale and market footprint.
• The required divestitures set a precedent for future M&A in the healthcare services sector, indicating that investors should anticipate regulatory demands for asset sales as a condition for approval in deals that consolidate market power.